Prostate cancer is the most common type of cancer found in men and usually begins without symptoms. The prostate cancer survival rate is greatly improved with early detection and treatment. UCLA’s Prostate Cancer Program offers the latest and most advanced care for both early and late stage prostate cancer. Our faculty are fellowship trained in urologic oncology and have been consistently ranked among the top prostate cancer practitioners in the United States.
UCLA urologist Christopher Saigal, MD, presented a live-streaming webinar to discuss the basics of prostate cancer, including anatomy, risk factors and common misconceptions.
UCLA urologists have been pioneers in developing new innovations and technologies leading to safer and more effective treatments for patients. For early stage, localized prostate cancer, we offer the entire spectrum of treatments, including:
Urinary Catheter Care
Learn what a catheter is, why you may need a catheter and how to care for your catheter.
What is a Urinary Catheter?
UCLA’s prostate cancer survival rates and measurements of treatment efficacy, including surgical margins and the lowest recordable PSA value, are among the best in the nation. Therefore, we monitor our results closely with outcomes databases and studies regarding the quality of life our patients achieve after prostate cancer treatment in order to improve the quality of our care and in order to better inform patients about the risk and benefits of all treatments. Because of the extensive basic and translational research done at UCLA in prostate cancer, we are actively studying new forms of treatment for patients with high-risk, locally advanced and metastatic prostate cancers. These include studies of molecularly targeted small molecules and antibodies, the latest in drugs that are able to target the genetic changes in an individual's tumors while sparing normal tissues. We are also on the leading edge of studies of nutrition and alternative medicines for prostate cancer.
The UCLA Prostate Cancer Program is the only program in Southern California and one of only three programs in the western U.S to be designated a Specialized Program of Research Excellence (SPORE) by the National Cancer Institute. With this distinction, UCLA earned an $11.5 million grant to enhance the program's ability to integrate laboratory and clinical researchers in a joint effort to improve detection, treatment and prevention of prostate cancer.
UCLA is committed to rapidly translating basic research from the laboratory to the clinic in order to advance care for men with prostate cancer. Prostate cancer is a disease that, when diagnosed and treated early, is highly curable - and one for which there are many different treatment options, each with its own pros and cons when it comes to efficacy and quality of life impact. UCLA is among the nation's most active centers for prostate cancer treatment, and few centers are as comprehensive as UCLA’s Prostate Cancer Program, which not only offers the full spectrum of treatment options, but also integrates research with clinical care.
Prostate Cancer Research >
Our overriding philosophy is that no one treatment is appropriate for all individuals and that treatments need to be tailored to the disease and to the individual's own values and goals.
What is Prostate cancer?
Prostate cancer is marked by an uncontrolled (malignant) growth of cells in the prostate gland. The prostate is the walnut-sized gland in men, located just below the bladder and in front of the rectum, surrounding the urethra – the tube that carries urine out of the bladder. The prostate produces and stores fluid that helps to make semen, and is involved in regulating bladder control.
Prostate cancer is the most common cancer among men in the United States , and the second-leading cause of cancer death, following lung cancer. It tends to be slow-growing, such that many men die of other diseases before the prostate cancer causes problems – in fact, autopsy studies have shown that upwards of three-fourths of men 80 and older have prostate cancer, though many were not diagnosed before the man died. The American Cancer Society estimates that one in six men will be diagnosed with prostate cancer during their lifetimes, but only one in 35 will die of the disease. However, certain prostate cancers are more aggressive and can quickly spread outside the confines of the prostate gland, which can be lethal. Early detection can ensure successful treatment. Overall, the five-year survival rate for prostate cancer is now up to 92 percent, in large part because of earlier diagnosis. Types of Prostate Cancer >
Meet Our Doctors >
The Department of Urology at UCLA is one of the most progressive and comprehensive urology programs in the country. Our faculty members work side by side with research scientists for new cures and treatments for bladder cancer.